- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
New Player in the Biosimilars Game: Aurobindo Pharma
Hyderabad, India-based Aurobindo Pharma is the latest addition to the world of biosimilars. The company announced that it has acquired 4 biosimilar products from TL Biopharmaceutical AG. Aurobindo plans to develop and commercialize the 4 molecules after it acquires the early stage data from TL.
An important molecule that the company will acquire with this agreement is the biosimilar for bevacizumab (Avastin), a monoclonal antibody developed by Genentech, which has been approved for treatment of a variety of tumor types: metastatic colorectal cancer, non—small cell lung cancer, platinum-resistant ovarian cancer, advanced cervical cancer, metastatic renal cell carcinoma, and recurrent glioblastoma. Bevacizumab is an angiogenesis inhibitor.
Aurobindo’s managing director, N. Govindarajan, said in a statement that the acquisition falls in line with the company’s strategy of establishing a biosimilar portfolio. Regulatory filings for the new acquisitions, 3 of which are in oncology molecules, are expected between 2020 and 2022.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
